YI
111, Inc.
NASDAQ · CNHealthcareMedical - Pharmaceuticals
$3.94+8.54%
Price as of Jul 20, 2026
YI financials
111, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $12.2B | $14.4B | $14.9B | $13.5B |
| Cost of revenue | $11.5B | $13.6B | $14.1B | $12.7B |
| Gross profit | $703.7M | $829.2M | $849.0M | $840.0M |
| Operating expenses | $713.7M | $827.1M | $1.2B | $1.2B |
| Operating income | -$10.0M | $2.1M | -$350.1M | -$371.0M |
| Net income | -$16.8M | -$64.7M | -$392.7M | -$416.9M |
| EBITDA | $1.8M | $24.6M | -$311.3M | -$321.8M |
| Basic EPS | $-7.42 | $-7.52 | $-46.58 | $-50.04 |
| Diluted EPS | $-7.42 | $-7.52 | $-46.58 | $-50.04 |
| Balance sheet | ||||
| Cash & equivalents | $561.7M | $462.3M | $603.5M | $673.7M |
| Total assets | $2.2B | $2.8B | $3.1B | $3.5B |
| Total liabilities | $2.0B | $2.4B | $2.8B | $2.8B |
| Stockholders’ equity | -$702.7M | -$642.6M | -$583.5M | -$414.6M |
| Total debt | $217.7M | $256.8M | $443.2M | $344.2M |
| Net debt | -$343.9M | -$205.5M | -$160.3M | -$329.5M |
| Cash flow | ||||
| Operating cash flow | $119.1M | $263.0M | -$447.2M | -$23.2M |
| Capital expenditure | -$4.5M | -$15.2M | -$9.8M | -$31.6M |
| Free cash flow | $114.7M | $247.8M | -$457.1M | -$54.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |